How would you manage a patient w/ DLBCL that progressed on/after EPOCH and subsequently treated with a CD19 Allo-CAR-T product within 90 days of receiving the aphaeresis product?

I'm sorry but the question is unclear. Did his disease progress after CD19 Allo-CAR-T? If so, I would offer commercially FDA-approved CD19-CAR-T. The fact the his disease progressed quickly after Allo-CAR is possibly due to lack of expansion and long-term persistence, which can be be mitigated by au...